Financials
- Financial year
- 2025
- Turnover
- €23.8m
- Loss
- -€1.4m
- Solvency
- 21.2%
Turnover▲ 5.2%
Net result
20182025
FAGRON BELGIUM
ActiveSummary
The annual accounts of FAGRON BELGIUM for financial year 2025 show a net loss of 5,311% of the equity at the start of that year. The 2025 annual accounts show equity of €1.7m and a net result of -€1.4m. The figures fluctuate too strongly year-on-year for a reliable trend projection. Its solvency ranks better than 23% of 6,056 sector peers (NACE 46, financial year 2025). The company has been active since 1959 and the Belgian Official Gazette contains no insolvency or warning signals. The computed 12-month bankruptcy probability is 1.1% (low).
Overview
Activity
Wholesale of pharmaceutical and medical goods
NACE 46460
Oldest company in Nazareth-De Pinte, Wholesale and retail trade sector1 site
Size
€23.8mturnover 2025
- Staff
- 57.1 FTE
- Equity
- €1.7m
- Loss
- -€1.4m
Structure
- Parent
- INFINITY PHARMA · 100%
- Cornelia de JongDirector
- PADILLA PAPACEIT RafaelDirector
Auditor: Deloitte Bedrijfsrevisoren/Réviseurs d’EntreprisesAccounts 44 days early
Why 54raises riskCapped at 59: a net loss of at least half of total assets or of the equity at the start of the financial yearLoss of €1.4m, the second in a row (financial year 2025)Equity €1.7m (21.2% of total assets)1 of the last 3 latelowers riskLegal form: public limited companyShow the evidence
Checked score
Score 2025
54
/ 100
Fair
Probability in this band: 1.5% to 4.2%
Financially better than 33% of its sector peers (NACE 46, medium-sized)
A net loss of at least half of total assets or of the equity at the start of the financial year caps the score at 59. Every signal that counts is listed under Signals.
Financial strength · tick = 2024
Weak
Solvency
46+21
equity 21.2% of total assets
Liquidity
20+9
short-term debt 78.6% · cash 10.0%
Profitability
5+3
return on assets -17.3%
Bankruptcy probability, 12 months
1.1%
Low
0%0.5%1.5%4%10%≥ 25%
About 1 in 100 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
11-2024: 0.7%
12-2024: 0.7%● unchanged vs 11-2024
01-2025: 0.7%● unchanged vs 12-2024
02-2025: 0.7%● unchanged vs 01-2025
03-2025: 0.7%● unchanged vs 02-2025
04-2025: 0.7%● unchanged vs 03-2025
05-2025: 0.7%● unchanged vs 04-2025
06-2025: 0.6%▼ -0.1 percentage points vs 05-2025lowest value
07-2025: 0.7%▲ +0.1 percentage points vs 06-2025
08-2025: 1.0%▲ +0.3 percentage points vs 07-2025
09-2025: 1.2%▲ +0.2 percentage points vs 08-2025
10-2025: 1.6%▲ +0.4 percentage points vs 09-2025highest value
11-2025: 1.6%● unchanged vs 10-2025highest value
12-2025: 1.6%● unchanged vs 11-2025highest value
01-2026: 1.6%● unchanged vs 12-2025highest value
02-2026: 1.5%▼ -0.1 percentage points vs 01-2026
03-2026: 1.5%● unchanged vs 02-2026
04-2026: 1.5%● unchanged vs 03-2026
05-2026: 1.5%● unchanged vs 04-2026
06-2026: 1.5%● unchanged vs 05-2026
07-2026: 1.1%▼ -0.4 percentage points vs 06-2026
08-2026: 1.1%● unchanged vs 07-2026
09-2026: 1.1%● unchanged vs 08-2026
10-2026: 1.1%● unchanged vs 09-2026
Credit of up to €90,000 on 30-day terms, only on tighter conditions
Net loss of at least half of total assets or of the equity at the start of the financial year.
Liquidity tight (current ratio 1.03, compared with 0.76 in 2024, below the usual 1.5; short-term debt: 78.6% and cash: 10% of total assets), and 78.8% of the assets are financed with debt and provisions.
How it is calculated
The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 46, medium-sized): better than 26% on solvency, 21% on liquidity, 3% on profitability and 81% on growth.
The bankruptcy probability was computed on 15-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).
Credit check for your own amount and term
Show the recommended maximum and see how the verdict changes with amount, term and advance.
Signals
Six signals.
lowers riskraises riskneutral
raises risk · Weak solvency vs sector
Solvency (equity / total assets) is in the sector's weakest quartile: better than 23% of 6056 sector peers (2025).
NBB · sector comparisonPosition among 6056 sector peers
Solvency
better than 23%
← weakest
strongest →
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 17-06-2026, 44 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
44 days early
2024
46 days late
2023
35 days early
2022
27 days early
2021
41 days early
2020
38 days early
2019
43 days early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
This company filed its last 7 accounts on average 26 days before the deadline; the sector median (NACE 46) for financial year 2024 is 3 days before the deadline, and 39% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 27 June (4 of the last 5 filed years within 30 days of that day).
Companies Code · seven monthsWhere today falls in the filing period
16-10-2026 today31-12-2026 year end31-07-2027 deadline
- Annual accounts filedfinancial year 2025 · full…
- Capital & sharesCapital increase · Capital contribution…
- Equity above €1mequity €1.7m ▲6,418%
Key points
- Risk: 4 loss-making years in a rowloss financial year 2025 -€1.4m View
- Positive: Equity rose in 2025from €25,600 to €1.7m ▲ 6,418% View
- Caution: Among the weakest 5% on net resultsector median €114,648 · 5,996 companies -€1.4m View
- Controlled by INFINITY PHARMAultimately: Fagron NV 100% View
- Active since 1959founded 05-05-1959 67 years View
By topic
Board & ownership
- Board
- 2 members
- Parent
- INFINITY PHARMA · 100%
- Auditor
- Deloitte Bedrijfsrevisoren/Réviseurs d’Entreprises
- Cornelia de JongDirector
- PADILLA PAPACEIT RafaelDirector
Network & group
- Group
- Fagron NV
- Connected companies
- 13
- Mergers and asset contributions
- 1
Timeline
- Events
- 83
- Since
- 1978
- Next accounts
- by 31-07-2027
- 31-12-2025Appointment: PwC Bedrijfsrevisoren BV (statutory auditor)
- 15-09-2025Annual accounts filed
- 26-06-2024Annual accounts filed
Company details
- Sites
- 1
- Legal form
- Public limited company
- Activity
- Wholesale of pharmaceutical and medical goodsNACE 46460
- Founded
- 05-05-1959
- Year ends
- 31-12
- Peppol
- Reachable for e-invoices
Articles of association
- Provisions read
- 1
- Purpose
- “De handel, de import en export van chemische, pharmaceutische, parapharmaceutische…” (deed in Dutch)
Go further with this company
How much credit can you give this customer, and on what payment terms?Credit check What should you check before you do business with this company?Supplier due diligence Is the workforce growing, and do people stay?Employer check Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check What support did similar companies receive that this one did not?Subsidies
Your own company? See how customers, suppliers and banks see it and what to improve first.
Investigating this company? Keep it with today's facts in a case file.